UNUSUAL PRESENTATION OF AN UNCOMMON LUNG MALIGNANCY

Ramaraju K1, Aggarwal B1, Kulsrestha R2, Chhabra SK1

ABSTRACT
Combined type of small cell lung carcinoma (SCLC) is a rare malignancy of the lung that is usually peripheral and diagnosed after resection. We report an unusual case of centrally located combined SCLC with squamous cell component that was diagnosed on endobronchial lung biopsy.

INTRODUCTION
Small cell lung carcinoma (SCLC) accounting for 20-25% of all lung cancers, remains one of the most frequently diagnosed cancers and the most common cause of cancer deaths worldwide1,2. Combined type has been reported to occur in 1 – 3% of all cases of SCLC. These tumours consist of SCLC with a component of squamous cell carcinoma and/or adenocarcinoma3. The rarity and heterogeneity of the tumour make the identification of combined SCLC difficult. Most are peripheral and diagnosed after resection. We report an unusual case of centrally located combined SCLC with squamous cell component that was diagnosed on endobronchial lung biopsy.

CASE REPORT
A 65 year-old male patient, current smoker (50 pack years) presented with complaints of dry cough and breathlessness for the past two months. He was also on treatment for hypertension for the last 3 years. Physical examination revealed no pallor, clubbing or lymphadenopathy. Examination of the respiratory system was not remarkable. The complete blood counts, electrocardiograph, and liver and kidney function tests (biochemistry) were within normal limits. The chest radiograph postero-anterior (PA) view taken one month apart showed a progressing mass lesion in the left paratracheal and parahilar region. Contrast enhanced computed tomography scan of the chest revealed a mass lesion with peripheral enhancement in the left hilum compressing the left main bronchus and encroaching on the wall of the descending aorta (Fig 1). Subcarinal lymph nodes were enlarged. Spirometry showed moderately severe airflow limitation with FEV1/FVC of 68%, forced expiratory volume in one second (FEV1) of 56% predicted and forced vital capacity (FVC) of 67% predicted. Change after bronchodilator was not significant. Fibroptic bronchoscopy under local anesthesia revealed extramural compression superomedially in the left main bronchus. A smooth surfaced growth was seen just beyond the compression. The overlying mucosa was hyperemic and the growth bled on touch. Biopsy was taken.

Bronchial aspirate did not show any atypical cells on microscopic examination. However, post-bronchoscopy sputum showed a cluster of small atypical cells with dark blue hyperchromatic nuclei, nuclear overlapping and scant cytoplasm. Occasional singly arranged atypical keratinized squamous cells having irregular, angulated cytoplasmic

Key words: Lung cancer, Combined carcinoma

Fig. 1: Contrast enhanced computed tomography scan of the chest showing the left hilar mass compressing the left main bronchus with enlarged subcarinal lymph nodes.

1Departments of Cardiorespiratory Physiology, Clinical Research Centre, 2Department of Pathology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi - 110 007 Correspondence: Prof. S.K. Chhabra, Department of Cardiorespiratory Physiology, Clinical Research Centre, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India. Email: skchhabra@emailcity.com
Received: September 2007
Accepted: February 2008
The slides were stained using streptavidin–biotin kit (DakoCytomation LSAB2 system -HRP). Positivity for Synaptophysin and CLA negativity were diagnostic for small cell carcinoma and ruled out the possibility of lymphoma (Fig 4).

A diagnosis of combined small cell lung carcinoma was thus made. The patient was explained the prognosis and referred for chemotherapy as surgical resection was ruled out due to the central location of the tumour and its close proximity to the aorta.

**DISCUSSION**

SCLC is classified as a separate subtype of lung carcinoma because of its clinical distinction, natural history and different growth characteristics. According to the World Health Organization (WHO) criteria with modifications by the Pathology committee of the International Association for the Study of Lung Cancer (IASLC), three subtypes of SCLC have been recognized: pure (classic), mixed and combined\(^4\). Mixed SCLC are tumours with a mixture of both SCLC and large cell carcinoma. Combined type SCLC has been estimated to comprise 1–3% of all types of chemonaive SCLC\(^4,5\). These tumors contain elements of SCLC mixed with a component of squamous cell carcinoma and/or adenocarcinoma\(^5,6\). The low incidence rate and the usually small and inadequate specimen obtained by bronchoscopic biopsy make it difficult to diagnose combined SCLC preoperatively\(^7\). Hage et al\(^8\) assessed 2115 patients with bronchogenic carcinoma and found that only 1.2% had combined SCLC. In none of the patients was the correct diagnosis established before operation. Most of the combined SCLC had stage 1 disease and surgical resection yielded a cumulative five-year survival of 31% while among those with stage 2 and 3 disease there were no survivors at five years. These outcomes were similar to those in patients with pure SCLC.
The clinical characteristics and course of the combined subtype of SCLC patients are similar to patients with other subtypes of SCLC. Patients with combined SCLC have a higher incidence of peripheral lesions. The central location of the tumour in the present case was unusual. Combined SCLC in the majority of cases reported has been a postoperative diagnosis using microscopic examination of the surgical resected specimens. Rare cases of combined SCLC have however been diagnosed using a transbronchial lung biopsy (TBLB) or mediastinoscopic biopsy. In the present case, the diagnosis of combined SCLC was established by histopathologic examination, including immunohistochemistry of the bronchoscopic biopsy specimen. While combined SCLC is as such rare, the atypical central location as in the present case is even rarer.

REFERENCES

1. Travis WD, Travis LB, Devesa SS. Lung Cancer. Cancer 1995; 75: 191-202.

2. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization Classification of lung tumours. Eur Respir J 2001; 18: 1059-1068.

3. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC). Am J Surg Pathol 2002; 26: 1184-1197.

4. Hirsch FR, Mathews MJ, Aisner S, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988; 62: 973-977.

5. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225 – 233.

6. Yesner R. Classification of lung cancer histology. N Engl J Med 1985; 312: 652-653.

7. Roggli VL, Vollmer RT, Greenberg SD, McGavern MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985; 16: 569-579.

8. Hage R, Elbers JR, Brutel de la Riviere A, Van den Bosch JMm. Surgery for combined type small cell lung carcinoma. Thorax 1998; 53: 450-453.

9. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. Journal of Clinical Oncology 1989; 7: 607-612.

10. Hsiao HH, Tsai HJ, Liu YC, et al. A rare case of combined small cell lung cancer with unusual soft tissue metastasis. Kaohsiung J Med Sci 2006; 22: 352-356.